Co-Authors
This is a "connection" page, showing publications co-authored by Antonio Abbate and Nicola Potere.
Connection Strength
1.650
-
Use of placebo in clinical trials in COVID-19 pandemic times: considerations on pros, cons, challenges and limitations. Minerva Med. 2021 Jul 16.
Score: 0.239
-
The role of IL-6 and IL-6 blockade in COVID-19. Expert Rev Clin Immunol. 2021 06; 17(6):601-618.
Score: 0.237
-
Response to: 'Correspondence on 'Interleukin-6 blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study' by Potere et al' by Buckley. Ann Rheum Dis. 2020 Sep 01.
Score: 0.225
-
Low-dose subcutaneous tocilizumab to prevent disease progression in patients with moderate COVID-19 pneumonia and hyperinflammation. Int J Infect Dis. 2020 Nov; 100:421-424.
Score: 0.224
-
Response to: 'Rational use of tocilizumab in COVID-19' by Jain and Sharma. Ann Rheum Dis. 2020 Jul 31.
Score: 0.224
-
Interleukin-6 receptor blockade with subcutaneous tocilizumab in severe COVID-19 pneumonia and hyperinflammation: a case-control study. Ann Rheum Dis. 2021 02; 80(2):1-2.
Score: 0.223
-
Acute complications and mortality in hospitalized patients with coronavirus disease 2019: a systematic review and meta-analysis. Crit Care. 2020 Jul 02; 24(1):389.
Score: 0.223
-
Canakinumab in a subgroup of patients with COVID-19. Lancet Rheumatol. 2020 Aug; 2(8):e457-ee458.
Score: 0.055